WEBULL

Prestige Consumer Healthcare (PBH) Is Down 11.0% After Earnings Miss And Surprise LaCorium Deal Disclosure - What's Changed

Simply Wall St · 3d ago
  • In May 2026, Prestige Consumer Healthcare reported fourth-quarter sales of US$281.62 million, down from US$296.52 million a year earlier, while net income and diluted EPS from continuing operations rose modestly.
  • The earnings shortfall versus prior projections, combined with the previously undisclosed US$150 million LaCorium Health acquisition and ensuing legal scrutiny, has raised fresh concerns about the company’s transparency and operational execution.
  • We’ll now examine how the earnings miss and surprise LaCorium acquisition disclosure may reshape Prestige Consumer Healthcare’s existing investment narrative.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Prestige Consumer Healthcare Investment Narrative Recap

To own Prestige Consumer Healthcare today, you need to believe its portfolio of everyday OTC brands can support steady earnings, even as supply issues and retailer behavior create choppy quarters. Right now, the key near term catalyst is execution on restoring product availability and stabilizing margins, while the biggest risk has shifted toward management’s credibility after the earnings miss and unexpected LaCorium disclosure; this legal and governance overhang looks material for sentiment.

The most relevant recent announcement is Prestige’s fiscal 2027 guidance for US$1,100 million to US$1,121 million of revenue and GAAP diluted EPS of US$4.31 to US$4.40. Against the backdrop of weaker fiscal 2026 results and the surprise LaCorium acquisition, that outlook gives investors a reference point for how management currently frames the balance between ongoing supply constraints, portfolio additions and the potential impact of execution risks on near term performance.

Yet behind the earnings headlines, the legal scrutiny around disclosure practices is something investors should be paying close attention to, because...

Read the full narrative on Prestige Consumer Healthcare (it's free!)

Prestige Consumer Healthcare's narrative projects $1.2 billion revenue and $243.2 million earnings by 2029. This requires 4.2% yearly revenue growth and about a $56.7 million earnings increase from $186.5 million today.

Uncover how Prestige Consumer Healthcare's forecasts yield a $78.50 fair value, a 68% upside to its current price.

Exploring Other Perspectives

PBH 1-Year Stock Price Chart
PBH 1-Year Stock Price Chart

One Simply Wall St Community member values Prestige at US$78.50, pointing to a materially higher long term outcome than the current share price implies. You should weigh that optimism against the recent concerns about transparency and execution, and consider how both could influence the company’s ability to deliver on its guidance.

Explore another fair value estimate on Prestige Consumer Healthcare - why the stock might be worth as much as 68% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.